Option chain shows key data for Scinai Immunotherapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Scinai Immunotherapeutics.

Scinai Immunotherapeutics (NASDAQ:SCNI) Stock, Option Chain

Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.

movers image

News

Intraday Update

Markets

Movers

Trading Ideas

ADTX

ADVM

AEHR

ALLR

AMIX

APVO

ASLN

ASML

ASST

CLIR

CRDO

CYCN

FDMT

FIVE

FUBO

GPCR

GTLB

HNST

JBHT

LAZR

LCFY

NAAS

NVDA

NVMI

OCTO

ONTO

QCOM

SAVA

SAVE

SCNI

SHIM

SIEB

SMTC

SNAP

SONM

TKNO

VKTX

VRPX

Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Crude Oil 6- logo

Eurozone

Commodities

LXEO

VTAK

Crude Oil Moves Lower; Goldman Sachs Posts Upbeat Results

Image49

AEON

AGRI

AREB

ASTL

COIN

DATS

EAST

FSLR

FUFU

HUMA

INOD

KZIA

LCID

MIRA

MLEC

MSTR

NOVA

PETZ

POWW

Qualigen Therapeutics, Inc. - Common Stock

QLGN

SEDG

SQNS

TSLA

UPST

Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics Ltd

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Scinai Immunotherapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/scni-stock-quote/"><strong>SCNI</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Scinai Immunotherapeutics reported earnings per share of -$4.00.</li><li>The company reported revenue of $284,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/scni-stock-earnings-scinai-immunotherapeutics-for-q2-of-2024/">SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q2 2024

Scinai Immunotherapeutics reports H1 results

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has secured a $2 million inve...

Scinai Secures $2M Investment Boost

Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics has successfully restructured its loan with the European Investm...

Scinai Immunotherapeutics Restructures Debt, Boosts Equity

Scinai Immunotherapeutics regains compliance with Nasdaq listing rule

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics Ltd. has successfully restructured its finances, converting near...

Scinai Immunotherapeutics Back on Track with Nasdaq

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has restructured a significan...

Scinai Immunotherapeutics Restructures Debt, Eyes Growth

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics Ltd. has struck a significant deal, granting exclusive global ri...

Scinai Immunotherapeutics Licenses Global Rights

Scinai Immunotherapeutics (SCNI) has released an update. Scinai Immunotherapeutics is set to hold its Annual General Meeting on November 21, 2024, ...

Scinai Immunotherapeutics to Hold Annual Shareholder Meeting

Press Releases

Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model

Small Cap

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb

Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity

Earnings

Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000

Scinai Regains Full Compliance with Nasdaq Listing Requirements

General

IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies

Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024

Comments

Scinai Immunotherapeutics

Scinai Immunotherapeutics (SCNI) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga